DoMore Diagnostics Welcomes Soroush Oskouei as AI Engineer
OSLO – October 27, 2025 – DoMore Diagnostics is delighted to announce that Soroush Oskouei is joining our team as an AI Engineer. Soroush brings strong academic credentials and applied research experience in medical imaging, machine learning, and applied mathematics. He is a PhD candidate in Medical Technology at the Norwegian University of Science and Technology (NTNU) and completed his Master’s degree at University of Eastern Finland.
Before joining DoMore Diagnostics, Soroush developed and deployed AI-based segmentation and classification models and has published his research in peer-reviewed journals in the field of digital pathology and applied machine learning. His expertise will support DoMore Diagnostics’ continued mission to personalize cancer care and deliver AI-powered tools that improve accuracy and efficiency.
“We are pleased to welcome Soroush to the DoMore Diagnostics team,” said Torbjørn Furuseth, CEO and Co-Founder. “His deep experience in AI image analysis and model development and his science-driven mindset are exactly what we need as we scale our solutions. I look forward to seeing the efforts he will bring to our digital biomarkers.”
Soroush added: “I am very excited to join DoMore Diagnostics. The combination of cutting-edge AI research and real-world clinical impact is exactly what motivates me. I look forward to contributing to the team and helping bring next-generation precision oncology to life.”
With Soroush joining the team, DoMore Diagnostics further strengthens its expertise in developing and optimizing AI algorithms and digital biomarkers, enhancing our ability to develop intelligent solutions that bring greater precision and clinical value to oncologists and cancer patients worldwide.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
DoMore Diagnostics has received funding from the European Innovation Council (EIC) Accelerator program.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Histotype Px is a registered trademark in the European Union. Trademark registration status may vary by country.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com